Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 9/20 | 0.46 |
| ▸ | F2 | P00734 | 3/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.45 |
| ▸ | TMPRSS6 | Q8IU80 | 3/20 | 0.45 |
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16166399 | 0.81 | POLB (0.56) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL4394590 | 0.81 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL15058154 | 0.80 | F2 (0.54) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL7335880 | 0.80 | POLB (0.51) | — | |
| SCHEMBL30954 | 0.79 | SMN1; SMN2 (0.50) | — | |
| Hydrochloric Acid SCHEMBL11303697 | 0.78 | SMN1; SMN2 (0.49) | — | |
| SCHEMBL8597983 | 0.77 | TGM2 (0.49) | — | |
| SCHEMBL16166446 | 0.76 | GRK2 (0.43) | — | |
| SCHEMBL7148427 | 0.75 | PRSS1 (0.61) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL2525700 | 0.74 | PRSS1 (0.62) | PRSS1F2PRSS2PRSS3TMPRSS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2978750-A2 | \"SYNTHESIS OF DABIGATRAN\ | USV Limited (IN) | 2016-02-03 | — | — | EP | claimed |
| WO-2014167577-A2 | \"SYNTHESIS OF DABIGATRAN\ | USV LIMITED (IN) | 2014-10-16 | — | — | WO | claimed |
| EP-2978750-B1 | \"SYNTHESIS OF DABIGATRAN\ | USV PRIVATE LTD (IN) | 2020-03-04 | — | — | EP | disclosed |
| US-9688657-B2 | Synthesis of dabigatran | USV PRIVATE LIMITED (IN) | 2017-06-27 | — | — | US | disclosed |
| US-20160060248-A1 | SYNTHESIS OF DABIGATRAN | USV PRIVATE LIMITED (IN) | 2016-03-03 | — | — | US | disclosed |
| EP-2978750-A2 | \"SYNTHESIS OF DABIGATRAN\ | USV Limited (IN) | 2016-02-03 | — | — | EP | disclosed |
| WO-2014167577-A2 | \"SYNTHESIS OF DABIGATRAN\ | USV LIMITED (IN) | 2014-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060248-A1 | SYNTHESIS OF DABIGATRAN | ESD, F2, PROC | PRSS1 347/4885F2 2/4885PRSS2 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.